促进抗菌药物研发的遗传学方法
Genetic Approaches to Facilitate Antibacterial Drug Development.
作者信息
Schnappinger Dirk
机构信息
Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10065.
出版信息
Cold Spring Harb Perspect Med. 2015 Feb 13;5(7):a021139. doi: 10.1101/cshperspect.a021139.
Abstract
Very few chemically novel agents have been approved for antibacterial chemotherapies during the last 50 yr. Yet new antibacterial drugs are needed to reduce the impact on global health of an increasing number of drug-resistant infections, including highly drug-resistant forms of tuberculosis. This review discusses how genetic approaches can be used to study the mechanism of action of whole-cell screening hits and facilitate target-driven strategies for antimicrobial drug development.
摘要
在过去50年里，获批用于抗菌化疗的化学结构新颖的药物极少。然而，仍需要新的抗菌药物来减轻包括高度耐药形式的结核病在内的越来越多耐药感染对全球健康的影响。本综述讨论了如何利用遗传学方法来研究全细胞筛选命中物的作用机制，并促进抗菌药物开发的靶点驱动策略。
相似文献
1
Genetic Approaches to Facilitate Antibacterial Drug Development.促进抗菌药物研发的遗传学方法
Cold Spring Harb Perspect Med. 2015 Feb 13;5(7):a021139. doi: 10.1101/cshperspect.a021139.
2
Novel and revisited approaches in antituberculosis drug discovery.新型及再探索的抗结核药物研发方法。
Curr Opin Biotechnol. 2017 Dec;48:94-101. doi: 10.1016/j.copbio.2017.03.023. Epub 2017 Apr 17.
3
The future for early-stage tuberculosis drug discovery.早期结核病药物发现的未来。
Future Microbiol. 2015;10(2):217-29. doi: 10.2217/fmb.14.125.
4
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发：现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
5
Bottlenecks and opportunities in antibiotic discovery against Mycobacterium tuberculosis.抗结核分枝杆菌抗生素药物研发的瓶颈与机遇。
Curr Opin Microbiol. 2022 Oct;69:102191. doi: 10.1016/j.mib.2022.102191. Epub 2022 Aug 12.
6
Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery.肽脱甲酰基酶——结核病治疗及抗菌药物研发的一个有前景的治疗靶点。
Expert Opin Ther Targets. 2009 Jul;13(7):753-65. doi: 10.1517/14728220903005590.
7
Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents.结核分枝杆菌全细胞筛选物作为潜在抗结核药物的开发。
J Med Chem. 2013 Oct 24;56(20):7755-60. doi: 10.1021/jm400381v. Epub 2013 Sep 23.
8
Bedaquiline-Resistant Tuberculosis Associated with Mutations.与突变相关的贝达喹啉耐药结核病
N Engl J Med. 2022 Jan 6;386(1):93-94. doi: 10.1056/NEJMc2103049.
9
Novel targets in M. tuberculosis: search for new drugs.结核分枝杆菌的新靶点：寻找新药物。
Trends Mol Med. 2011 Jan;17(1):25-33. doi: 10.1016/j.molmed.2010.10.004. Epub 2010 Nov 9.
引用本文的文献
1
CRISPRi knockdown of mycobacterial tkt gene potentiates the anti-mycobacterial activity of phyto-compounds from selected medicinal plants.CRISPRi技术敲低分枝杆菌的tkt基因可增强所选药用植物中植物化合物的抗分枝杆菌活性。
BMC Complement Med Ther. 2025 Jul 4;25(1):240. doi: 10.1186/s12906-025-04987-8.
2
Exploration of novel bioactive compounds from the microbiome of fish and shellfish as an alternative to replace antibiotic drugs in aquaculture farming.探索来自鱼类和贝类微生物群的新型生物活性化合物，以替代水产养殖中的抗生素药物。
Gut Microbiome (Camb). 2025 May 14;6:e8. doi: 10.1017/gmb.2025.6. eCollection 2025.
3
Uncovering the potentiality of quinazoline derivatives against Pseudomonas aeruginosa with antimicrobial synergy and SAR analysis.揭示喹唑啉衍生物在铜绿假单胞菌中的抗菌协同作用及构效关系研究。
J Antibiot (Tokyo). 2024 Jun;77(6):365-381. doi: 10.1038/s41429-024-00717-3. Epub 2024 Mar 21.
4
Chemical genetic approaches for the discovery of bacterial cell wall inhibitors.用于发现细菌细胞壁抑制剂的化学遗传学方法。
RSC Med Chem. 2023 Aug 30;14(11):2125-2154. doi: 10.1039/d3md00143a. eCollection 2023 Nov 15.
5
Genome-scale analysis of essential gene knockout mutants to identify an antibiotic target process.基于全基因组分析必需基因敲除突变体来鉴定抗生素作用靶标过程。
Antimicrob Agents Chemother. 2023 Dec 14;67(12):e0110223. doi: 10.1128/aac.01102-23. Epub 2023 Nov 15.
6
Antimicrobial Compounds from Microorganisms.微生物来源的抗菌化合物。
Antibiotics (Basel). 2022 Feb 22;11(3):285. doi: 10.3390/antibiotics11030285.
7
The pursuit of mechanism of action: uncovering drug complexity in TB drug discovery.作用机制的探索：揭示结核病药物研发中的药物复杂性
RSC Chem Biol. 2021 Apr 1;2(2):423-440. doi: 10.1039/d0cb00226g. Epub 2021 Jan 13.
8
Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in .MmpL3 表达的双向调控鉴定和验证了. 中 MmpL3 功能的抑制剂
ACS Infect Dis. 2021 Jan 8;7(1):141-152. doi: 10.1021/acsinfecdis.0c00675. Epub 2020 Dec 15.
9
Tuberculosis drug discovery in the CRISPR era.CRISPR 时代的结核病药物发现。
PLoS Pathog. 2019 Sep 19;15(9):e1007975. doi: 10.1371/journal.ppat.1007975. eCollection 2019 Sep.
10
Promoter mutagenesis for fine-tuning expression of essential genes in Mycobacterium tuberculosis.启动子诱变技术用于精细调控结核分枝杆菌中必需基因的表达。
Microb Biotechnol. 2018 Jan;11(1):238-247. doi: 10.1111/1751-7915.12875. Epub 2017 Oct 27.
本文引用的文献
1
Regulated Expression Systems for Mycobacteria and Their Applications.分枝杆菌的调控表达系统及其应用
Microbiol Spectr. 2014;2(1). doi: 10.1128/microbiolspec.MGM2-0018-2013.
2
Tuberculosis drug discovery in the post-post-genomic era.后基因组时代的结核病药物发现。
EMBO Mol Med. 2014 Feb;6(2):158-68. doi: 10.1002/emmm.201201772. Epub 2014 Jan 8.
3
Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing.色氨酸生物合成可保护分枝杆菌免受 CD4+T 细胞介导的杀伤。
Cell. 2013 Dec 5;155(6):1296-308. doi: 10.1016/j.cell.2013.10.045.
4
A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence.一种用于确定药物靶点的遗传策略，这些药物可预防细菌持续存在。
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19095-100. doi: 10.1073/pnas.1315860110. Epub 2013 Nov 4.
5
Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis.结核分枝杆菌中新的药物靶点和耐药机制的鉴定。
PLoS One. 2013 Sep 23;8(9):e75245. doi: 10.1371/journal.pone.0075245. eCollection 2013.
6
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.发现 Q203，一种治疗结核病的有效临床候选药物。
Nat Med. 2013 Sep;19(9):1157-60. doi: 10.1038/nm.3262. Epub 2013 Aug 4.
7
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.药物化学家优化抗结核药物先导化合物的独特挑战
Bioorg Med Chem Lett. 2013 Sep 1;23(17):4741-50. doi: 10.1016/j.bmcl.2013.07.006. Epub 2013 Jul 12.
8
Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32.二芳基乙烯基类化合物通过靶向 FadD32 抑制分枝菌酸生物合成并杀死结核分枝杆菌。
Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11565-70. doi: 10.1073/pnas.1302114110. Epub 2013 Jun 24.
9
Identification of a small molecule with activity against drug-resistant and persistent tuberculosis.鉴定一种对耐药性和持久性结核病有活性的小分子。
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):E2510-7. doi: 10.1073/pnas.1309171110. Epub 2013 Jun 17.
10
Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis.抗结核噻吩类化合物定义了 Pks13 在分枝菌酸生物合成中的需求。
Nat Chem Biol. 2013 Aug;9(8):499-506. doi: 10.1038/nchembio.1277. Epub 2013 Jun 16.
Zotero 插件